

Edgar Filing: MEDCOM USA INC - Form 10QSB

MEDCOM USA INC
Form 10QSB
November 13, 2007

=====
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-QSB

(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (D)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2007.

[] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (D)
OF THE SECURITIES EXCHANGE ACT

For the transition period from N/A to N/A

Commission File No. 0-25474

MEDCOM USA, INCORPORATED
(Name of small business issuer as specified in its charter)

DELAWARE 65-0287558
State of Incorporation IRS Employer Identification No.

7975 NORTH HAYDEN ROAD, SUITE D-333
SCOTTSDALE, AZ 85258
(Address of principal executive offices)
(480) 675-8865
(Issuer's telephone number)

Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.

Yes X No

Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act).

Yes No X

The number of shares of the issuer's common equity outstanding as of
November 3, 2007 was 94,620,217 shares of common stock.

Transitional Small Business Disclosure Format (check one):

Yes No X

Edgar Filing: MEDCOM USA INC - Form 10QSB

1

MEDCOM USA INCORPORATED
INDEX TO FORM 10-QSB FILING
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2007

TABLE OF CONTENTS

PART I		PAGE
FINANCIAL INFORMATION		
Item 1. Financial Statements		
Condensed Consolidated Balance Sheet		
As of September 30, 2007.		3
Condensed Consolidated Statements of Operations		
For the Three months ended September 30, 2007		
and 2006.		4
Condensed Consolidated Statements of Cash Flows		
For the Three months ended September 30, 2007		
and 2006.		5
Notes to Condensed Financial Statements.		6-12
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations		12-18
Item 3. Control and Procedures.		18-19
PART II		
OTHER INFORMATION		
Item 1. Legal Proceedings.		20
Item 2. Changes in Securities and Small Business Issuer Purchases of Equity Securities		20
Item 3. Defaults upon Senior Securities.		20
Item 4. Submission of Matters to a Vote of Security Holders.		20
Item 5. Other Information.		20
Item 5. Exhibits		20
CERTIFICATIONS		
Exhibit 31 - Management certification		20-24
Exhibit 32 - Sarbanes-Oxley Act		20-24

2

PART I - FINANCIAL INFORMATION

ITEM 1 - FINANCIAL STATEMENTS

Edgar Filing: MEDCOM USA INC - Form 10QSB

MEDCOM USA, INC.
 CONDENSED CONSOLIDATED BALANCES SHEETS
 AS OF SEPTEMBER 30, 2007

ASSETS:

	2007
<hr/>	
CURRENT ASSETS	
Cash	\$ 91,318
Licensing contracts - current portion, net	909,151
Prepaid expenses and other current assets	240,390
	<hr/>
Total current assets	1,240,859
PROPERTY AND EQUIPMENT, net	456,813
Licensing contracts - long-term portion, net	391,284
Note receivable affiliates	62,641
Other assets	17,657
	<hr/>
TOTAL ASSETS	\$ 2,169,254
	<hr/> <hr/>

LIABILITIES AND STOCKHOLDERS' DEFICIENCY:

CURRENT LIABILITIES:

Accounts payable	\$ 197,831
Accrued expenses and other liabilities	52,619
Dividend payable	23,750
Notes from affiliates	450,000
Deferred revenue - current portion	498,970
Licensing obligations - current portion	2,332,768
	<hr/>
Total current liabilities	3,555,938
Licensing obligations - long-term portion	3,011,173
Deferred Revenue	1,135,944
	<hr/>
Total liabilities	7,703,055
	<hr/> <hr/>

STOCKHOLDERS' DEFICIENCY:

Convertible preferred stock, series A \$.001par value, 52,900 shares designated, 4,250 issued and outstanding	4
Convertible preferred stock, series D \$.01par value, 50,000 shares designated, 2,850 issued and outstanding	29
Common stock, \$.0001 par value, 175,000,000 shares authorized, 94,620,217 issued and outstanding as of September 30, 2007	9,463
Treasury stock	(37,397)
Paid-in capital	84,883,309
Accumulated deficit	(90,389,209)
	<hr/>
Total stockholders' deficiency	(5,533,801)
	<hr/> <hr/>

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY	\$ 2,169,254
	<hr/> <hr/>

Edgar Filing: MEDCOM USA INC - Form 10QSB

The accompanying notes are an integral part of these condensed consolidated financial statements.

3

MEDCOM USA, INC.

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006

	2007	2006
REVENUES:		
Terminal sales	\$ -	\$ 26,423
Service	663,571	921,344
Licensing fees	273,485	653,424
	937,056	1,601,191
COST OF DELIVERABLES:	331,606	554,571
GROSS PROFIT	605,450	1,046,620
OPERATING EXPENSES:		
General and administrative expenses	620,931	973,082
Sales and marketing expenses	16,800	30,153
Depreciation and amortization	-	442,158
Total operating expenses	637,731	1,445,393
OPERATING LOSS	(32,281)	(398,773)
OTHER (INCOME) AND EXPENSES		
Interest expense	199,419	98,101
Interest Income	(68,847)	(103,603)
Legal settlement	-	39,600
Impairment of assets	-	27,040
Total other expense	130,572	61,138
LOSS BEFORE INCOME TAXES	(162,853)	(459,911)
INCOME TAX BENEFIT	-	-
NET LOSS	\$ (162,853)	\$ (459,911)
NET LOSS PER SHARE:		
Basic and diluted:	\$ (0.00)	\$ (0.01)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:		
Basic and diluted:	93,871,358	75,151,497

Edgar Filing: MEDCOM USA INC - Form 10QSB

The accompanying notes are an integral part of these condensed consolidated financial statements

4

MEDCOM USA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006

	2007	2006
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net loss	\$ (162,853)	\$ (459,910)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	55,296	442,158
Issuance of stock as consideration for services	-	151,632
Allowance for doubtful accounts	-	-
Impairment of assets	-	13,100
Changes in operating assets and liabilities:		
Prepaid and other current assets	(43,251)	69,364
Accounts payable	74,676	(238,961)
Accrued expenses and other liabilities	(1,822)	-
Deferred revenue	(461,444)	(893,441)
Net cash provided by (used in) operating activities	(539,398)	(916,058)
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchasing of equipment	(28,123)	(133,580)
Licensing contracts - current portion	(118,900)	120,552
Licensing contracts - long-term portion	155,937	353,721
Notes from affiliates	145,000	(858,000)
Net cash provided by (used in) investing activities	153,914	(517,307)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Licensing obligation - current portion	(3,057)	(258,963)
Licensing obligation - long-term portion	(301,002)	(424,946)
Cost of raising capital	(48,350)	-
Proceeds from sale of common stock	803,001	2,178,991
Net cash provided by financing activities	450,592	1,495,082
(DECREASE) INCREASE IN CASH	65,108	61,717
CASH, BEGINNING OF YEAR	26,210	1,148
CASH, END OF YEAR	\$ 91,318	\$ 62,865

SUPPLEMENTAL CASH FLOW INFORMATION:

Edgar Filing: MEDCOM USA INC - Form 10QSB

	2007	2006
	-----	-----
Interest paid	\$ 199,419	\$ 98,000
	=====	=====

The accompanying notes are an integral part of these condensed consolidated financial statements

5

MEDCOM USA INCORPORATED
NOTES TO CONDENSED FINANCIAL STATEMENTS THREE MONTHS ENDED SEPTEMBER 30, 2007
AND 2006

1. BASIS OF PRESENTATION

MedCom USA, Inc. (the "Company") a Delaware corporation was formed in August 1991 under the name Sims Communications, Inc. The Company's primary business was providing telecommunications services. In 1996 the Company introduced four programs to broaden the Company's product and service mix: (a) cellular telephone activation, (b) sale of prepaid calling cards, (c) sale of long distance telephone service and (d) rental of cellular telephones using an overnight courier service. With the exception of the sale of prepaid calling cards and cellular telephone activation, the other programs were discontinued in December 1997. The Company changed its name to MedCom USA, Inc. in October 1999. During the fiscal years of 1999 and continuing through present, the Company directed its efforts in medical information processing.

2. GOING CONCERN

The accompanying condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America which contemplate continuation of the Company as a going concern. However, the Company has year end losses from operations and had minimal revenues from operations the three months ended September 30, 2007. During three months ended September 30, 2007 the Company incurred a net loss of \$162,853 and has an accumulated deficit of \$90,389,209. Further, the Company has inadequate working capital to maintain or develop its operations, and is dependent upon funds from private investors and the support of certain stockholders.

These factors raise substantial doubt about the ability of the Company to continue as a going concern. The condensed financial statements do not include any adjustments that might result from the outcome of these uncertainties. In this regard, Management is proposing to raise any necessary additional funds through loans and additional sales of its common stock. There is no assurance that the Company will be successful in raising additional capital.

3. INTERIM FINANCIAL STATEMENTS

The accompanying interim unaudited condensed financial information has been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations, although management believes that the disclosures are adequate to make the information presented not misleading. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position of the Company as of

Edgar Filing: MEDCOM USA INC - Form 10QSB

September 30, 2007 and the related operating results and cash flows for the interim period presented have been made. The results of operations of such interim periods are not necessarily indicative of the results of the full fiscal year. For further information, refer to the financial statements and footnotes thereto included in the Company's 10-KSB and Annual Report for the fiscal year ended June 30, 2007.

6

4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Summarized below are the significant accounting policies of MedCom USA, Inc. ("we," "MedCom," or the "Company"). Unless otherwise indicated, amounts provided in these notes to the financial statements pertain to continuing operations.

Revenue Recognition

Statement of Position Software Revenue Recognition ("SOP") 97-2 applies to all entities that license, sell, lease, or market computer software. It also applies to "hosting" arrangements in which the customer has the option to take possession of the software. Hosting arrangements occur when end users do not take possession of the software but rather the software resides on the vendor's or a third party's hardware, and the customer accesses and uses the software on an as-needed basis over the Internet or some other connection. It does not, however, apply to revenue earned on products containing software incidental to the product as a whole or to hosting arrangements that do not give the customer the option of taking possession of the software.

SOP 97-2 allows for revenue to be recognized in accordance with contract accounting when the arrangement requires significant production, modification, or customization of the software. When the arrangement does not entail such requirements, revenue should be recognized when persuasive evidence of an agreement exists, delivery has occurred, the vendor's price is fixed or determinable, and collectibility is probable.

The largest part of revenues stems from vendors' license fees associated with software. The Company recognizes revenue from license fees when the software is shipped to the customer. The amount and timing of revenue recognition is based on the multiple-element arrangements that provide for multiple software deliverables [e.g., software products, upgrades or enhancements, post contract customer support (PCS), or other services]. In hosting arrangements that are within the scope of SOP 97-2, multiple elements might include specified or unspecified upgrade rights, in addition to the software product and the hosting service. The software provider often charges a single fee that must be allocated to the products delivered.

In an arrangement with multiple deliverables, Emerging Issues Task Force Revenue Arrangement with Multiple Deliverables ("EITF") 00-21 requires that the delivered items be considered a separate unit of accounting if the delivered items have value to the customer on a stand-alone basis, if there is objective and reliable evidence of the fair value of the undelivered items, and if the arrangement includes a general right of return for the delivered item, or if delivery or performance of the undelivered items is considered probable and substantially in the control of the vendor. EITF 00-21 requires allocation of the vendor's fee to the various elements based on relative fair value of each element's stand-alone value.

In general, both SOP 97-2 and EITF 00-21 require allocating revenue to all of the elements of a multiple-deliverable arrangement using the relative fair value method, where objective and reliable evidence of fair value is present for all

Edgar Filing: MEDCOM USA INC - Form 10QSB

the products contained in the group.

Management has established vendor-specific objective evidence ("VSOE") for access fee, equipment, provider enrollment fees, EDI connectivity fees, payer/provider fees, benefit verification fees, referral transfer fees, service authorization fees, claim status, training, support, program upgrades, carrier editions, and customized reports. Revenue is accordingly allocated and recognized based on the value of deliverables.

The Company has substantial upfront expenses such as commission, royalties, software portal, and the software deliverables and pays those costs at the execution of the contract. The Company accumulates the entire contract of licensing and gateway access fees and records it as the licenses and gateway access fees receivables. The Company recognizes revenue in accordance with SOP 97-2 when the software is delivered to the professional

7

and recognizes the remaining portion of the contract over the life of the contract. The Company recognizes the revenue of the contract at the time of the deliverables and execution of the contract since the Company has substantial costs upfront at the time of delivery. The remaining portion is recognized monthly in accordance with the agreement. The Company further accrues the prepaid licensing expense, accrued deliverables under the fixed and determinable licensing arrangement.

The Company has adopted the Securities and Exchange Commission's Staff Accounting Bulletin (SAB) No. 104, Revenue Recognition, which provides guidance on the recognition, presentation and disclosure of revenue in financial statements.

5. EQUITY

During three months ended September 30, 2007 and 2006:

QUARTER ENDED	STOCK ISSUED FOR CASH	CASH RECEIVED	STOCK ISSUED FOR SERVICES	STOCK ISSUED FOR Warrants Exercised
September 30, 2006	7,384,373	\$ 2,178,991	1,837,331	-
<hr style="border-top: 1px dashed black;"/>				
Total Issued	7,384,373	\$ 2,178,991	1,837,331	-
September 30, 2007	1,847,357	\$ 803,001	-	-
<hr style="border-top: 1px dashed black;"/>				
Total Issued	1,847,357	\$ 803,001	-	-

During the period ended September 30, 2006, the Company issued 7,384,373 shares of its common stock for \$2,178,991. The shares were issued to third parties in a private placement of the Company's common stock. The shares were sold throughout the quarter ended September 30, 2006, ranging from \$.75 per share at the beginning of the period to \$.25 per share at the end of the period. Commissions of approximately \$350,000 were recorded as a charge in additional paid in capital as direct costs associated with the raising of equity capital.

In the past, the Company has issued shares of its common stock as consideration to consultants for the fair value of the services rendered. The value of those

Edgar Filing: MEDCOM USA INC - Form 10QSB

shares is determined based on the trading value of the stock at the dates on which the agreements were entered into for the services and the value of services rendered. During the period ended September 30, 2006, the Company granted to consultants, 1,837,331 shares of common stock valued between \$.75 - \$.25. The value of these shares issued were expensed during the year.

In September 30, 2007 the Company issued 1,847,357 shares of its common stock for \$803,001. The shares were issued to third parties in a private placement of the Company's common stock. The shares were sold throughout the quarter ended September 30, 2007, ranging from \$.35 per share at the beginning of the period to \$.48 per share at the end of the period. Commissions of approximately \$48,350 are recorded as a charge in additional paid in capital as direct costs associated with the raising of equity capital.

In the past, the Company issues common stock for services to vendors and consultants in lieu of cash.

8

6. RELATED PARTY TRANSACTIONS

The Company's president and chairman is a significant shareholder and is its sole officer and director of the Company. The chairman controls American Nortel Communications, Inc. which is also a significant shareholder of the Company. During the year ended June 30, 2002, the Company moved its administrative offices into space occupied by this related entity. The Company shares office space and management and administrative personnel with this related entity. Certain of the Company's personnel perform functions for the related entity but there was no allocation of personnel related expenses to the related entity in the three months ended September 30, 2007 and 2006.

The Company frequently receives advances, and advances funds to an entity controlled by the Company's president, which is a significant shareholder of the Company to cover short-term cash flow deficiencies. In the three months ended June 30, 2007 the chairman advanced \$305,000. In the three months ended September 30, 2007 the chairman advanced \$145,000. The balance due to this affiliate three months ended September 30, 2007 and 2006 was \$450,000 and \$794,626 respectively. The advances are generally short term in nature with an interest rate of 9%. The advances of \$450,000 still remain outstanding as of September 2007.

The Company paid management fees of \$450,000 to Wilcom, Inc., an entity owned by the Company's president.

ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Management's Discussion and Analysis contains various "forward looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, regarding future events or the future financial performance of the Company that involve risks and uncertainties. Certain statements included in this Form 10-QSB, including, without limitation, statements related to anticipated cash flow sources and uses, and words including but not limited to "anticipates", "believes", "plans", "expects", "future" and similar statements or expressions, identify forward looking statements. Any forward-looking statements herein are subject to certain risks and uncertainties in the Company's business, including but not limited to, reliance on key customers and competition in its markets, market demand, product performance, technological developments, maintenance of relationships with key suppliers, difficulties of hiring or retaining key personnel and any changes in current accounting rules, all of which may be beyond the control of the Company. The Company adopted at

Edgar Filing: MEDCOM USA INC - Form 10QSB

management's discretion, the most conservative recognition of revenue based on the most astringent guidelines of the SEC in terms of recognition of software licenses and recurring revenue. Management will elect additional changes to revenue recognition to comply with the most conservative SEC recognition on a forward going accrual basis as the model is replicated with other similar markets (i.e. SBDC). The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth therein.

Forward-looking statements involve risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. Factors and risks that could affect our results and achievements and cause them to materially differ from those contained in the forward-looking statements include those identified in the section titled "Risk Factors" in the Company's Annual Report on Form 10-KSB for the year ended June 30, 2007, as well as other factors that we are currently unable to identify or quantify, but that may exist in the future.

9

In addition, the foregoing factors may affect generally our business, results of operations and financial position. Forward-looking statements speak only as of the date the statement was made. We do not undertake and specifically decline any obligation to update any forward-looking statements.

OVERVIEW

MedCom USA, Inc. (the "Company") a Delaware corporation was formed in August 1991 under the name Sims Communications, Inc. The Company's primary business was providing telecommunications services. In 1996 the Company introduced four programs to broaden the Company's product and service mix: (a) cellular telephone activation, (b) sale of prepaid calling cards, (c) sale of long distance telephone service and (d) rental of cellular telephones using an overnight courier service. With the exception of the sale of prepaid calling cards and cellular telephone activation, the other programs were discontinued in December 1997.

The Company changed its name to MedCom USA, Inc. in October 1999. During the fiscal years of 1999 and continuing through present, the Company directed its efforts in medical information processing.

HEALTHCARE TRANSACTION PROCESSING

MEDCOM SYSTEM

The Company provides innovative technology-based solutions for the healthcare industries that enable users to efficiently collect, use, analyze and disseminate data from payers, health care providers and patients. The MedCom System currently operates through a point-of-sale terminal or web portal. The point-of-sale terminals are purchased from Hypercom Corporation (Hypercom). The Company business plan consists of offering a service bundled package that would have the capability of processing unlimited claims and eligibility verification for monthly service fees.

The Company's "web portal" encourages customers to process their medical claims through an online portal. Many customers purchase the terminal for the front office and the portal system for the back office to take advantage of the ease of both products.

Edgar Filing: MEDCOM USA INC - Form 10QSB

FINANCIAL TRANSACTION SERVICES

The Company's credit card center and check services provides a combination of services designed to improve collection and approvals of credit/debit card payments along with the added benefit and convenience of personal check guarantee from financial institutions.

Easy-Pay is an accounts receivable management program that allows a provider to swipe a patient's credit card and store the patient's signature in the terminals, and bill the patient's card at a later date when it is determined what services rendered were not covered by the patient's insurance. Also, Easy-Pay allows patient's the added benefit and convenience of a one-time payment option or a recurring installment payments that will be processed on a specified date determined by the provider and patient. These options insure providers that payments are timely processed with the features of electronic accounts receivable management. These services are all deployed thorough point-of-sale terminals or web portal. Using the MedCom system, medical providers are relieved of many of the problems associated with billings and account management, and results in lower administrative documentation and costs.

10

PATIENT ELIGIBILITY

The MedCom System is also an electronic processing system that consolidates insurance eligibility verification, processes medical claims, and monitors referrals. The MedCom System allows a patient's primary care physician to request approval from the patient's insurance carrier or managed care plan for a referral to a secondary physician or specialist. The secondary physician or specialist can use the MedCom system to verify referrals are approved by the patient's insurance carrier. The MedCom system's referral capabilities reduce documentation and administrative costs which results in increased productivity and greater patient information for the specialist, as well as a written record of the referral authorization.

The MedCom System can record and track encounters between patients and health care providers for performance evaluation and maintenance of records. After examining a patient the physician enters a patient's name, procedure code and diagnostic code at a nearby terminal. This information is then uploaded to MedCom's computer network, processed and transmitted back to the provider formatted in both summary and/or detailed reports, and as a result healthcare providers' reimbursements are accelerated and account receivables are reduced. In managements' opinion, the average time it takes the healthcare providers to collect payments from insurance carriers and plans decreases from an average of 89 days to 7-21 days. Health care providers will benefit from a 100% paperless claim processing system.

Presently, the MedCom system was able to retrieve on-line eligibility and authorization information from approximately 450 medical insurance companies and plans. Included in this group is the newly activated Medicare Part A & B eligibility for all 50 states. This gives us access to over 42 million lives. The system also electronically processes and submits claims for its healthcare providers to over 1,700 companies. These insurance providers include CIGNA, Prudential, Oxford Health Plan, United Health Plans, Blue Cross, Medicaid, Aetna, Blue Cross/Blue Shield, and Prudential.

11

COMPETITION

Edgar Filing: MEDCOM USA INC - Form 10QSB

Competing health insurance claims processing and/or benefit verification systems include WebMD (HLTH), NDC Health (NDC), and Per-se Technologies (PSTI). There are similar companies that compete with the Company with respect to its financial transaction processing services performed by the MedCom system. These companies compete with the Company directly or to some degree. Many of these competitors are better capitalized than the Company, and maintain a significant market share in their respective industries.

The Company offers multiple training options for its products and services and is easily accessed at www.MedComUSA.com. Onsite training and teleconferencing,

and technical support assistance are also features offered to health care providers. Also, a 24-hour terminal replacement program and system upgrades are offered.

MARKETING STRATEGY

MedCom has broadened marketing strategy to reduce cost and increase efficiency. The Company has employed telesales strategy to decrease dependency on individual sales personnel. The Company just completed its final phase of its portal software development which has broadened the sales model to both a terminal and portal sale. The Company has entered into telesales agreements which have implemented the new marketing strategy. The completion of the portal will increase sales to hospitals which results in multiple sales. In addition, the portal has become popular for individual doctors, dentist, and other healthcare professionals which often results in a single or possibly multiple sales. The Company has focused its sales to hospitals as a growing revenue source.

In the past the Company built its marketing around a strategy of expanding its sales capacity by using experienced external Independent Sales Organizations (ISO) and putting less reliance on an internal sales force. MedCom has set-up these Independent Sales Organizations (ISOs) to market and distribute the MedCom System throughout the U.S. Financial service companies comprise an important sales channel that views the healthcare industry as an important growth opportunity. Also 6% of all healthcare payments are made with a credit card today. However, according to a recent survey 55% of all consumers would prefer to pay doctor and hospital visits by credit/debit card.

MedCom has been expanding its position with hospitals and working closely with hospital consultants and targeted seminars. The Company, with its new Online web portal product and Medicare access, is becoming an increasingly valuable tool for the outpatient and faculty practice areas of hospitals. While the ISO groups focus on individual doctors, dentists and clinics, our hospital team is focusing on multiple unit sales opportunities with hospitals around the country.

SERVICE AGREEMENTS

During June 2005, the Company entered into a service agreement with TESIA-PCI, Inc. This agreement was to replace and service and support at a minimum, 1,500 POS terminals inclusive of eligibly, claims processing, credit card processing for TESIA's dental providers.

PATENT

Card Activation Technologies Inc. ("Card") is a Delaware corporation headquartered in Chicago, Illinois that owns proprietary patented payment transaction technology used for electronic activation of phone, gift and affinity cards. MedCom owns 60,000,000 shares of common stock of Card which represents 41% of the issued

and outstanding shares of Card.

The patent was transferred to Card by MedCom on the formation of Card and in exchange for 146,770,504 shares of Common Stock.

Card was incorporated in August 2006 in order to own and license the assigned patent which covers payment transaction technology and the process for taking a card with a magnetic strip or other data capture mechanism and processing transactions or activating the card. This process is utilized for prepaid phone cards, gift cards, and debit-styled cards. As of the date of this report, Card has entered into a license agreement with McDonald's Corporation. Card has one principal asset, the patented payment transaction technology assigned from MedCom, and one full time and one part-time employee. Card does not expect to commence full scale operations or generate additional revenues until late 2007. Since incorporation, Card has not made any significant purchases or sale of assets, nor has Card been involved in any mergers, acquisitions or consolidations. Card has filed four lawsuits to enforce its patented technology and has sent license agreement requests to a number of companies in order to obtain license agreements with entities that Card believes are infringing its patent.

Card has the ability to market and sell licensing opportunities for the patented technology of processing debit-styled transactions, including processing transactions with debit, phone and gift cards and also activating and adding value to those debit-styled cards. New View Technologies, which was acquired by MedCom USA, developed the patent and all patents were ultimately assigned to Card.

REVENUES

A sales staff meets with a dental or medical professionals. During that initial meeting a demo is displayed so the professional has first hand knowledge of the software and its use. At the time of the meeting a noncancellable licensing agreement is executed along with a service agreement. The license agreement indicates the life of the agreement if the customer wants check readers, pin pads, portal wedge, etc. with the software. These units allow the professional to swipe a credit card and medical card for the software to read.

The professional executes the licensing agreement which states the terms for a period of 24 - 60 month agreements, number of portal/units needed, at which location the portals will be used, the monthly licensing amount, (which varies per contract) type of contract whether dental or medical, the amount of the gateway access fee (usually \$24.95 per month which includes provider enrollment), EDI connectivity, a the monthly maintenance charges that are billed when used as commercial benefit verification, Referral transactions, claims status, service authorizations, maintenance, training, support, programs upgrades, carrier additions, and customized reports. The professional then provides MedCom a voided check or credit card number to automatically withdraw or charge the licensing fee and gateway access fees on a monthly basis. Also those automatic withdrawals include the maintenance charges based upon usage. The professional also agrees to allow MedCom to provide merchant services for Visa/MasterCard. MedCom further agrees that the monthly fees charged for gateway access and licensing fees will commence with in 10 day so of the execution of the noncancellable agreements.

MedCom has substantial upfront expenses such as commission, royalties, software portal, and the software deliverables and pays those costs at the execution of the contract. The Company accumulates the entire contract of licensing and gateway access fees and record as the licenses and gateway access fees

Edgar Filing: MEDCOM USA INC - Form 10QSB

receivables. The Company recognizes revenue in accordance with SOP 97-2 when the software is delivered to the professional and recognizes the remaining portion of the contract over the life of the contract. The Company recognizes the revenue of the contract at the time of the deliverables and execution of the contract since the Company has

13

substantial costs upfront at the time of delivery. The remaining portion is recognized monthly in accordance with the agreement. The Company further accrues the prepaid licensing expense, accrued deliverables under the fixed and determinable licensing arrangement.

The Company continues to recognize transaction fees as they receive them. The Company collects other fees based upon usage of the software and are not fixed fee such as gateway access and licensing fees and are part of the deliverables such as Provider enrollment, EDI Connectivity, Payer/Provider, Benefit Verification - Govt Billings, Referral Transfers - Govt billing, Benefit Verification - Commercial, Referral Transfer - Commercial, Claim Status, Service Authorization, Maintenance, Training, Support, Program Upgrades, Carrier Editions, and Customized Reports. The Company calls these fees transaction fees, they are not a fixed or determinable therefore are not accrued but are recognized when used by the customer.

The Company enters into a long term debt and long term receivable for the life of the license agreement which is non cancelable agreement. The Company collects the monthly licensing and gateway access fees every 30 days over the life of the contract. The Company does not collect the entire contract within 30 days but over the terms of the agreement therefore records deferred revenue for the portion of the contract that is recognized over the contract.

The Company finances the licensing fees agreement while the gateway access fees are received over the life of the contract. The license fees are financed through Ladco in prior periods and in fiscal 2006 and 2007 through LeeCo. The Company as a standard financing the agreement through LeeCo through the term of the contract.

Revenues from the MedCom system are generated through the sale of the portal software, software terminals, and processing insurance benefit eligibility/verification, insurance claims, and financial transaction processing. The Company receives a fixed amount per software portal and software terminal, and also receives fees for each transaction processed through the MedCom System. Revenue sources include fees for financial transactions processed through the software portal and software terminal, fees for collection of receivables if the Company provides billing services, fees associated with reimbursements made by insurance carriers for submitting claims that are processed electronically, fees for using the system's referral program and, fees for processing uploaded data. The Company also markets a complete billing service using the MedCom System for hospitals and large practice groups. The Company receives a percentage of the billing amount collected under these arrangements.

The Company has adopted the Securities and Exchange Commission's Staff Accounting Bulletin (SAB) No. 104, which provides guidance on the recognition, presentation and disclosure of revenue in financial statements.

ADDITIONAL INFORMATION

MedCom files reports and other materials with the Securities and Exchange Commission. These documents may be inspected and copied at the Commission's Public Reference Room at 450 Fifth Street, N.W., Washington, D.C., 20549. You

Edgar Filing: MEDCOM USA INC - Form 10QSB

can obtain information on the operation of the Public Reference Room by calling the Commission at 1-800-SEC-0330. You can also get copies of documents that the Company files with the Commission through the Commission's Internet site at www.sec.gov.

RESULTS OF OPERATIONS

Revenues for the three months ended September 30, 2007 decreased to \$937,056 from \$1,601,191 during 2006 as 56% reduction. This decrease in revenue is directly the result of changes in the Company's strategic direction in core operations. The Company continues to aggressively pursue and devote its resources and focus its direction in electronic medical transaction processing. The Company's agreement with its credit facility in connection with the licensing of terminals and portal transactions therewith, the Company must defer revenue

14

on licensing agreement of the terminals and portal software. The decline in revenues is directly related in 2006 the Company executed large licensing agreements with large hospital groups such as Mount Sinai, St. Vincent, Beth Israel, and Continuum Partners. The large hospital groups that licensed our portals licensed at a minimum of 35 portal systems pergroup. In the case of St. Vincent our portal system is used exclusively by all of their hospital facilities. However, in September 30, 2007 the Company was licensing to more individual doctor and dental groups that were directly related to our decrease in revenues.

The Company further refocused its sales to large practice management groups to sell multiple web portals and further have expanded its exposure and future sales with a large dental group. The Company is negotiating and developing relationships with the practice management and dental groups and the Company will not realize those efforts until fiscal year 2008.

Cost of deliverables for the quarter ended September 30, 2007 decreased to \$331,606 as compared to 2006 of \$554,571 a 60% reduction. The Company has developed the MedComConnect portal package that will decrease the cost of deliverables as the Company focuses on the sale of the portal software which rendered the medical terminals sales no longer the core revenue model for the Company. The decrease in cost of deliverables is directly related to the decrease in revenues from the two quarter ended September 30, 2007. Also the decrease is related to the decrease then elimination of 25% royalty payments to third parties. Further the Company no longer pays commission on future revenues from its noncancellable licensing agreements. Commissions are paid at inception of the licensing agreement at a 10% rate and there are no future payments on residuals revenues from gateway access fees and licensing fees. The Company paid the future royalty obligation and commitment and is no longer obligated to pay royalties now and in the future. In the prior period comparative there was a spike in costs with TESIA, a larger vendor contract.

Selling expenses for the quarter ended September 30, 2007 decreased to \$16,800 as compared to 2006 of \$30,153, a 56% reduction. This decrease is primarily the result of marketing efforts and includes commissions paid to internal sales personnel to market the Company's products and services. The Company has introduced the telesales marketing strategy for less expensive sales force and more effective in the future.

General and administrative expenses for the quarter ended September 30, 2007 decreased to \$620,931 as compared to 2006 of \$973,082 a 64% reduction. This decrease is attributed to the Company's reduction of workforce in their New York

Edgar Filing: MEDCOM USA INC - Form 10QSB

operations as the Company has streamlined overall employee use. That is the Company has implemented and advanced its in-house software to perform many of the services the prior employees were performing manually.

Interest expense for quarter ended September 30, 2007 increased to \$199,419 as compared to 2006 of \$98,101 a 49% increase. This increase is a result of renegotiation of the Company's credit facility with Ladco who charged a higher interest rate but required a penalty payment. Also, expenses were incurred and paid on notes the Company has outstanding with LeeCo. Further the Company's renegotiation has reduced the accrual of interest below 3% until paid in full in 2009. We have also have been paying down the LeeCo obligation which has grown from the increase in financing through LeeCo Financial Inc. The payments to Ladco represented a high interest rate and it has been a Company initiative to reduce the Ladco debt to zero. Interest income for quarter ended September 30, 2007 decreased to \$68,847 as compared to 2006 of \$103,603. The decrease is due to the reduction in current sales of the portal software from our license agreements. The licensing agreements are noncancellable licensing of our portal software in which we capitalize the receivable and liability related to the life of the licensing agreement. The accrual of these licensing agreements results in interest income.

The loss for quarter ended September 30, 2007 decreased to (\$162,853) as compared to 2006 of (\$459,911). The decrease is due to the reduction in revenue, sales force, royalty expense, commissions, and reduction in operations in our New York facility.

15

No tax benefit was recorded on the expected operating loss for September 30, 2007 and 2006 as required by Statement of Financial Accounting Standards No. 109, Accounting for Income Taxes. For the quarter ended we do not expect to realize a deferred tax asset and it is uncertain, therefore we have provided a 100% valuation of the tax benefit and assets until we are certain to experience net profits in the future to fully realize the tax benefit and tax assets.

LIQUIDITY AND CAPITAL RESOURCES

The Company's operating requirements have been funded primarily on its sale of licensing agreements with hospitals, medical, and dental professionals and sales of the Company's common stock. During the quarter ended September 30, 2007, the Company's net proceeds from the licensing of the Company's software portals were \$273,485 as compared to 2006 of \$653,424. The Company received \$803,001 as compared to 2006 of \$2,178,991 in proceeds from the sale of common stock. The Company believes that the cash flows from its monthly service and transaction fees are inadequate to repay the capital obligations and has relied upon the sale of common stock through a private place to sustain its operations.

Cash (used) operating activities for the quarter ended September 30, 2007 was (\$539,398) compared to (\$916,058) for 2006. The Company's focus on core operations results in an increase in licenses receivable. The Company receives payments from customers automatically through electronic fund transfers. Collection cycles of the monthly noncancellable licenses are generally paid monthly. The Company has grown its operations to begin to reduce the deficit cash flow positions. However the Company is still operating in a deficit. The Company reduced its expenses by exercising a put option to buyout the royalty payments to third parties. The Company issued common stock valued at for quarter ended September 30, 2006 of \$151,632. The Company had depreciation and amortization expenses for quarter ended September 30, 2007 of \$55,296 as compared to 2006 of \$442,158. The reduction in deprecation is directly related to the write off of the terminal asset capitalized in prior fiscal periods.

Edgar Filing: MEDCOM USA INC - Form 10QSB

Cash provided by (used in) investing activities was \$153,914 for quarter ended September 30, 2007, compared to (517,307) for 2006. Streamlining operations and capital budget curtailment practices promoted a reduction in equipment purchases for the Company. However, the Company continues to employ software development teams that are upgrading the existing proprietary software in our terminal and portal licensing agreement sold. The quarter ended September 30, 2007 the chairman advanced funds of \$145,000 as compared to \$0 for 2006.

Cash provided by financing activities was \$450,592 for quarter ended September 30, 2007 as compared to \$1,495,082 for 2006. Financing activities primarily consisted of proceeds from the increase in the financing of our licensing agreement through LeeCo. The Company does not have adequate cash flows to satisfy its obligations although have improved cash flow and anticipates have adequate cash flows in the upcoming fiscal period. The Company received proceeds from the sale of common stock for quarter ended September 30, 2007 of \$803,001 as compared to 2006 of \$2,178,991. The Company decreased its licensing debt for quarter ended September 30, 2007 of \$304,059 as compared to \$683,909. The Company decrease the cost of raising capital was \$48,350 for quarter ended September 30, 2007 as compared to \$0 for 2006.

The Company has used funds advanced from an affiliated entity that is controlled by the Company's chairman and chief executive officer. As of quarter ended September 30, 2007 the Company maintained a note payable from this entity for the amount of \$450,000 as compared to fiscal 2006 of \$794,626 including accrued interest.

The Company has funding agreements with LeeCo Financial Service Inc. and Ladco Financial Group who provide exclusive funding for the License agreement between the Company and Licensing. The funding groups

16

accept contracts and adopt the same terms and conditions that the Company and Licensing have agreed. In prior years Ladco required to personally guarantee the licensing agreements which were a financial burden to the Company. In fiscal 2006, the Company no longer sought funding through Ladco and has consistently sought the funding of LeeCo. LeeCo does not require personal guarantees of licensing agreements other than hospital agreements. LeeCo requires the Company to personally guarantee the hospital agreements due to the size and volume of transaction with the terminal and web portals.

The Company expects increased cash flow from its existing services fees which include transaction processing, benefit claims processing, direct terminal sales, and credit card processing. The decrease in cost of deliverables is directly related to the sales through our telesales. Further we anticipate increase income from our TESIA-PC contracts that have a higher volume of credit card processing in which we receive a fee per month on all transactions with a 15 cent per transaction fee in fiscal 2008.

The Company is looking at expanding the market for its services and considering prospective acquisitions that would complement the existing revenue model. The Company has investigated two possible acquisitions but until due diligence is completed and negotiations have been completed we will continue to look for possible new horizontal business mergers.

On September 14, 2006 the Company renegotiated the Ladco debt. The Company agreed to pay penalties and late fees of \$268,585.73 in exchange the renegotiated balance would only carry an interest rate of 3% reduced from 26% in the original note. The Company originally owed \$3,015,063 and renegotiated the balance to \$3,880,500 which included the accrued penalties and late fees. Further the Company would be able to pay the remaining balance of the note for

Edgar Filing: MEDCOM USA INC - Form 10QSB

39 months at \$99,500 payments per month until paid in full. Under the renegotiated note the note matures on October 2009.

LeeCo agreement adopts the agreement that the Company executes with the customer. LeeCo collects all funds through ACH and is paid from those proceeds. The excess of those proceeds are collected by the Company. LeeCo holds as collateral all the proceeds from the customer leases, access fees and all cash collections and is secured from all assets of the Company.

The licensing agreement is executed between the professional and the MedCom. During the course of the agreement the Company ACH's the accounts of the professionals and LeeCo collects the fees and reduces the liability for the licensing fees collected and returns any excess transaction fees to the Company. The professional does not finance their agreement with LeeCo, the Company finances the agreement. LeeCo is not a related party of the Company. The financing of the licensing agreement is calculated as part of our revenue recognition process as the monthly collection of the licensing fee is recorded against the outstanding balance. Revenue is not recognized in excess of the cash received from our financing of the likening agreement in accordance with SAB 101. The guarantees that are provided in connection with the hospital agreements have not changed our revenue recognition process except the accrual of the interest expense related to the unpaid balances.

The Company has a fixed and determinable licensing fee and gateway access fees. The Company has all customer agreements over a period of 24 -60 months. This period the Company updates software, and provides various transaction fees outlined as deliverables. The Company receives payments through out the term of the agreement. The Company incurs upfront expenses in the initial software installation that is outlined in the deliverables and continues to service the customer with the remaining deliverables through out the terms of the contract. Revenue is recognized when the customer pays the ongoing payment through out the term of the contract. Revenue is recognized at the initial installation based upon the cost of deliverables at the time of installation.

17

The Company has a fixed and determinable licensing arrangement as the Company enforces all licensing agreements as they are noncancellable, the Company has never altered the terms of the agreement with the original licensing agreement, the Company has incremental risk in this arrangement. The Company recognizes revenue over the terms of the agreement and further recognizes revenue based upon the costs of deliverable that is required in the initial installation of the software and continues to provide deliverables in accordance with the terms of the agreement.

The Company has a standard practice to enter into a financing arrangement with LeeCo and does not provide a concession which makes it fixed and determinable licensing arrangement. MedCom has incremental risk in the financing arrangement with LeeCo and thus has fixed and determinable licensing arrangement.

The customer does not arrange any financing of the software. The Company has recourse in the financing arrangement. The Company recognizes revenue upon delivery of the software and over the term of the agreement based up on the deliverables delivered under the terms of the agreement.

The Company participates in the financing of the customers' term contract. The Company recognizes revenues to the extent of the expenses paid upfront for the deliverables and then recognizes revenue over the term of the contract. The Company defers any revenue of the contract and recognizes that deferred revenue over the remaining term of the contract.

Edgar Filing: MEDCOM USA INC - Form 10QSB

ITEM 3. CONTROLS AND PROCEDURES

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

a) Evaluation of Disclosure Controls and Procedures.

Under the supervision and with the participation of our management, including our Chief Executive Officer and Principal Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act"). Disclosure controls and procedures are the controls and other procedures that we designed to ensure that we record, process, summarize and report in a timely manner the information we must disclose in reports that we file with or submit to the Securities and Exchange Commission under the Exchange Act. Based on this evaluation, our Chief Executive Officer and our Principal Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.

Disclosure controls and procedures are controls and procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our principal executive officer and our principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

b) Changes in Internal Control over Financial Reporting

During the Quarter ended September 30, 2007, there was no change in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

18

OTHER CONSIDERATIONS

There are numerous factors that affect our business and the results of its operations. Sources of these factors include general economic and business conditions, federal and state regulation of business activities, the level of demand for the Company's product or services, the level and intensity of competition in the medical transaction processing industry and the pricing pressures that may result, the Company's ability to develop new services based on new or evolving technology and the market's acceptance of those new services, the Company's ability to timely and effectively manage periodic product transitions, the services, customer and geographic sales mix of any particular period, and the ability to continue to improve infrastructure including personnel and systems, to keep pace with the growth in its overall business activities.

FORWARD-LOOKING STATEMENTS

Except for historical information contained herein, this Form 10-QSB contains express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. The Company may make written or oral forward-looking statements

Edgar Filing: MEDCOM USA INC - Form 10QSB

from time to time in filings with the SEC, in press releases, or otherwise. The words "believes," "expects," "anticipates," "intends," "forecasts," "project," "plans," "estimates" and similar expressions identify forward-looking statements. Such statements reflect the current views with respect to future events and financial performance or operations and are only as of the date the statements are made. Forward-looking statements involve risks and uncertainties and readers are cautioned not to place undue reliance on forward-looking statements. The Company's actual results may differ materially from such statements. Factors that cause or contribute to such differences include, but are not limited to, those discussed elsewhere in this Form 10-QSB, as well as those discussed in Form 10-KSB which is incorporated by reference in this Form 10-QSB.

Management believes that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance that the results contemplated in such forward-looking statements will be realized. The inclusion of such forward-looking information should not be regarded, as a representation that the future events, plans, or expectations contemplated will be achieved. The Company undertakes no obligation to publicly update, review, or revise any forward-looking statements to reflect any change in expectations or any change in events, conditions, or circumstances on which any such statements are based. Our filings with the Securities Exchange Commission, including the Form 10-KSB, and may be accessed at the SEC's web site, www.sec.gov.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

MedCom is involved in various legal proceedings and claims as described in our Form 10-KSB for the year ended June 30, 2007. No material developments occurred in any of these proceedings during the quarter ended September 30, 2007. The costs and results associated with these legal proceedings could be significant and could affect the results of future operations.

ITEM 2. CHANGES IN SECURITIES AND SMALL BUSINESS ISSUER PURCHASES OF EQUITY SECURITIES

There were no changes in securities and small business issuer purchase of equity securities during the period ended September 30, 2007.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

19

There were no defaults upon senior securities during the period ended September 30, 2007.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

There were no matters submitted to the vote of securities holders during the period ended September 30, 2007.

ITEM 5. OTHER INFORMATION

None

Exhibits

31.1 Certification of Chief Executive Officer Pursuant to Section 302

Edgar Filing: MEDCOM USA INC - Form 10QSB

of the Sarbanes-Oxley Act

- 31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act.
- 32.1 Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act.
- 32.2 Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Registrant
Date: November 13, 2007

MedCom USA Incorporated
By: /s/ William P. Williams

William P. Williams
Chairman, President Chief Executive
Officer (Principle Executive Officer,
Principle Financial Officer)